(FDA这篇是在说抗体检测不能判断免疫能力或本身对病毒的抗性)
原文标题：
FDA In Brief: FDA Advises Against Use of SARS-CoV-2 Antibody Test Results to
Evaluate Immunity or Protection From COVID-19, Including After Vaccination
原文连结：
https://tinyurl.com/34znv66p
发布时间：
May 19, 2021
原文内容：
“The FDA is reminding the public of the limitations of COVID-19 antibody, or
serology, testing and providing additional recommendations about the use of
antibody tests in people who received a COVID-19 vaccination.
Antibody tests can play an important role in identifying individuals who may
have been exposed to the SARS-CoV-2 virus and may have developed an adaptive
immune response. However, antibody tests should not be used at this time to
determine immunity or protection against COVID-19 at any time, and especially
after a person has received a COVID-19 vaccination.
The FDA will continue to monitor the use of authorized SARS-CoV-2 antibody
tests for purposes other than identifying people with an adaptive immune
response to SARS-CoV-2 from a recent or prior infection.”
大致翻译如下
FDA认为可以用SARS-CoV-2抗体来进行辨识接触病毒历史
但FDA表示抗体并不能代表免疫力或保护力(减少重症)
"尤其是使用过COVID-19之疫苗后"
(虽然这是常识啦XDDDD)
心得/评论：
该篇宣告和国产疫苗本身只有中和抗体数据没绝对关系
国产疫苗二期只有中和抗体效价的数据 (补充，中和抗体和总抗体是不同的东西)
也就是说，依照此数据推估出来的效力或是保护力，都无法经过检验或承认
所以上至高官或抗疫英雄，下至人体受试者或网拍业者
说国产疫苗二期数据好棒棒效力一定很棒的都是未经过验证说法
(我原本说是谣言，经过版友指正认为带有情绪且容易误导为无效，这边修正)
没有三期双盲测试的数据根本无法谈效力，美国FDA也不会承认
用抗体想去建立VE模型? 目前是没有任何学理上的支持
一个没有效力数据的疫苗要怎么进行战略调度呢?
至于出口，就不用说了